Loading viewer...
investor_presentation
Format: PDF investor_presentation
Corporate Presentation February 2018 © 2018, Iovance Biotherapeutics, Inc.
Corporate Presentation
© 2018, Iovance Biotherapeutics, Inc.This presentation contains forward -looking statements reflecting management’s current beliefs andexpectations .These forward looking
statements canbeidentified with words such as“expects”, “plans”, “projects”, “potential”, “suggests”, “may”, orsimilar expressions .Such
forward -looking statements involve known andunknown risks, uncertainties andother factors thatmaycause theactual results tobe
materially different from anyfuture results, performance orachievements expressed orimplied bysuch statements .Forward -looking
statements inthispresentation include statements regarding (i)thesuccess andtiming ofourproduct development activities andclinical
trials, (ii)ourability, andtheability ofourcommercial partners, tomanufacture, process anddeliver ourproduct candidates andtofurther
improve onthemanufacturing process, (iii)thesizeofthepotential markets forourproduct candidates, (iv)ourability todevelop next
generation TILandother more effective andefficient therapeutics, (v)ourability tomaintain ourcollaborations andother relationships with
third parties, (vi)ourability toattract andretain keymanagement andscientific personnel, (vii)ourability toobtain andmaintain intellectual
property protection forourproduct candidates, (viii)ourability tocompete withother therapeutics thattarget thesame indications asour
product candidates, and(ix)ourability toachieve ourmanufacturing, clinical, regulatory, andother keymilestones, including theprogression
ofthird-party sponsored studies, which mayrequire additional clinical trials andmanufacturing development .
Formore detailed information about therisks anduncertainties thatcould cause actual results todiffer materially from those implied by,or
anticipated in,these forward -looking statements, please refer totheRiskFactors section oftheCompany’s Annual Report onForm 10-K
andsubsequent updates thatmaybecontained intheCompany’s Quarterly Reports onForm 10-Qandcurrent reports onForm 8-Konfile
with theSEC.Forward -looking statements speak onlyastothedate they aremade .Except asrequired bylaw,theCompany does not
undertake toupdate forward -looking statements toreflect circumstances orevents that occur after thedate theforward looking
statements aremade .Thispresentation does notconstitute anoffer tosellorbuysecurities, andnooffer orsalewillbemade inanystate
orjurisdiction inwhich such offer orsalewould beunlawful prior toregistration orqualification under thesecurities lawsofanysuch state
orjurisdiction .Forward -Looking Statements
© 2018, Iovance Biotherapeutics, Inc. 2(1) Rosenberg, S. A., et al. Clinical Cancer Research, 2011, 17, 4550.
(2) Goff, S. L. et al. Journal of Clinical Oncology, 2016, 34(20), 2389 -2397.
(3) https://seer.cancer.gov/statfacts/html/all.html
Data from third parties may not be representative of Iovance’s data.
© 2018, Iovance Biotherapeutics, Inc.TIL Approach is a Proven Treatment for Solid Tumors
•Developing and commercializing tumor
Preview truncated — download the full document for the complete content.
investor_presentation
35 Pages
investor_presentation
21 Pages
Resources Connection, Inc
AGBA Group 2023 Investor Presentation
investor_presentationinvestor_presentation
34 Pages
AGBA Group Holding Limited